TissGeneSummary for AADACL2 |
Gene summary |
Basic gene information | Gene symbol | AADACL2 |
Gene name | arylacetamide deacetylase-like 2 | |
Synonyms | - | |
Cytomap | UCSC genome browser: 3q25.1 | |
Type of gene | protein-coding | |
RefGenes | NM_207365.3, | |
Description | - | |
Modification date | 20141207 | |
dbXrefs | HGNC : HGNC | |
Ensembl : ENSG00000197953 | ||
HPRD : 14705 | ||
Vega : OTTHUMG00000155914 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_AADACL2 | |
BioGPS: 344752 | ||
Pathway | NCI Pathway Interaction Database: AADACL2 | |
KEGG: AADACL2 | ||
REACTOME: AADACL2 | ||
Pathway Commons: AADACL2 | ||
Context | iHOP: AADACL2 | |
ligand binding site mutation search in PubMed: AADACL2 | ||
UCL Cancer Institute: AADACL2 | ||
Assigned class in TissGDB* | B | |
Included tissue-specific gene expression resources | HPA,TiGER,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | SkinUterus | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | SKCMUCEC,UCS | |
Reference showing the relevant tissue of AADACL2 | ||
Description by TissGene annotations |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID |
Top |
TissGeneExp for AADACL2 |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
BRCA | -0.147545102 | 0.971252267 | -1.118797368 | 1.80E-12 | 7.92E-12 |
LUSC | 2.395986787 | 0.432982865 | 1.963003922 | 7.60E-06 | 1.75E-05 |
COAD | -0.408882821 | 2.479932564 | -2.888815385 | 7.89E-12 | 1.60E-10 |
STAD | -0.084864071 | 1.680170304 | -1.765034375 | 5.95E-07 | 1.08E-05 |
HNSC | 2.284890435 | 4.17529276 | -1.890402326 | 0.00239 | 0.007198795 |
Top |
TissGene-miRNA for AADACL2 |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for AADACL2 |
TissGeneSNV for AADACL2 |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.A197V | UCEC | 2 |
p.L14F | SKCM | 2 |
p.P288S | SKCM | 1 |
p.I185V | BLCA | 1 |
p.R130K | LUAD | 1 |
p.M56I | SKCM | 1 |
p.A163V | UCEC | 1 |
p.T352A | STAD | 1 |
p.K399T | UCEC | 1 |
p.Y253H | UCEC | 1 |
p.E51K | SKCM | 1 |
p.E28* | BLCA | 1 |
p.G303E | CESC | 1 |
p.R355* | UCEC | 1 |
p.L252V | LUAD | 1 |
p.T378S | LGG | 1 |
p.I65L | THYM | 1 |
p.T242N | LUAD | 1 |
p.T255N | LGG | 1 |
p.P90A | LUSC | 1 |
p.T21A | PAAD | 1 |
p.E367K | PAAD | 1 |
p.A5V | SKCM | 1 |
p.L401V | BLCA | 1 |
p.R384H | LIHC | 1 |
p.L14I | UCEC | 1 |
p.A5T | HNSC | 1 |
p.R182Q | UCS | 1 |
p.R384H | LGG | 1 |
p.S308L | THCA | 1 |
p.R388K | GBM | 1 |
p.M56I | LUSC | 1 |
p.H269P | STAD | 1 |
p.D341N | SKCM | 1 |
p.N193D | SKCM | 1 |
p.G347E | SKCM | 1 |
p.D188E | LUSC | 1 |
p.D391N | SKCM | 1 |
p.Y58F | COAD | 1 |
p.Y109C | COAD | 1 |
p.M64I | CESC | 1 |
p.R92Q | SKCM | 1 |
p.L173P | SKCM | 1 |
p.R355Q | SKCM | 1 |
p.R182Q | SKCM | 1 |
p.R105Q | COAD | 1 |
p.C184Y | STAD | 1 |
p.Y334N | LUAD | 1 |
p.R384C | UCEC | 1 |
p.T132M | LGG | 1 |
p.E289Q | LUAD | 1 |
p.S308X | READ | 1 |
p.D294Y | UCEC | 1 |
p.I89T | LUAD | 1 |
p.W31* | SKCM | 1 |
p.Y78N | STAD | 1 |
p.E60* | UCEC | 1 |
p.G2W | ESCA | 1 |
p.D324N | SKCM | 1 |
p.R105X | STAD | 1 |
p.W262* | LUAD | 1 |
p.E29D | STAD | 1 |
p.S306R | SKCM | 1 |
p.I212M | SKCM | 1 |
p.L36F | UCEC | 1 |
p.E207K | SKCM | 1 |
p.A263V | UCEC | 1 |
p.A162V | LUAD | 1 |
p.P380S | SKCM | 1 |
p.A148P | LUSC | 1 |
p.D346N | BLCA | 1 |
p.D244N | BLCA | 1 |
p.R105* | STAD | 1 |
p.D144E | STAD | 1 |
p.R266K | BRCA | 1 |
p.G9R | SKCM | 1 |
p.R130T | LGG | 1 |
p.A162D | LUSC | 1 |
p.T333I | GBM | 1 |
p.Y94N | STAD | 1 |
p.W31X | SKCM | 1 |
p.D205N | SKCM | 1 |
p.S375L | SKCM | 1 |
Top |
TissGeneCNV for AADACL2 |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for AADACL2 |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
Top |
TissGeneNet for AADACL2 |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for AADACL2 |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for AADACL2 |
TissGeneDrug for AADACL2 |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for AADACL2 |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |